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Prevention Program 
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Jonathan E. Shaw8, Robyn J. Tapp1,9,10, Paul Z. Zimmet11, Sajitha Balachandran4,12, Suman S. Shetty1, 
Zahra Aziz1,13 and Ajay Mahal1 
Abstract 
Background: Data on the cost-effectiveness of lifestyle-based diabetes prevention programs are mostly from high-
income countries, which cannot be extrapolated to low- and middle-income countries. We performed a trial-based 
cost-effectiveness analysis of a lifestyle intervention targeted at preventing diabetes in India. 
Methods: The Kerala Diabetes Prevention Program was a cluster-randomized controlled trial of 1007 individuals 
conducted in 60 polling areas (electoral divisions) in Kerala state. Participants (30–60 years) were those with a high 
diabetes risk score and without diabetes on an oral glucose tolerance test. The intervention group received a 12-
month peer-support lifestyle intervention involving 15 group sessions delivered in community settings by trained 
lay peer leaders. There were also linked community activities to sustain behavior change. The control group 
received a booklet on lifestyle change. Costs were estimated from the health system and societal perspectives, with 
2018 as the reference year. Effectiveness was measured in terms of the number of diabetes cases prevented and 
quality-adjusted life years (QALYs). Three times India’s gross domestic product per capita (US$6108) was used as the 
cost-effectiveness threshold. The analyses were conducted with a 2-year time horizon. Costs and effects were 
discounted at 3% per annum. One-way and multi-way sensitivity analyses were performed. 
Results: Baseline characteristics were similar in the two study groups. Over 2 years, the intervention resulted in an 
incremental health system cost of US$2.0 (intervention group: US$303.6; control group: US$301.6), incremental 
societal cost of US$6.2 (intervention group: US$367.8; control group: US$361.5), absolute risk reduction of 2.1%, and 
incremental QALYs of 0.04 per person. From a health system perspective, the cost per diabetes case prevented was 
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US$95.2, and the cost per QALY gained was US$50.0. From a societal perspective, the corresponding figures were 
US$295.1 and US$155.0. For the number of diabetes cases prevented, the probability for the intervention to be 
cost-effective was 84.0% and 83.1% from the health system and societal perspectives, respectively. The 
corresponding figures for QALY gained were 99.1% and 97.8%. The results were robust to discounting and 
sensitivity analyses. 
Conclusions: A community-based peer-support lifestyle intervention was cost-effective in individuals at high risk of 
developing diabetes in India over 2 years. 
Trial registration: The trial was registered with Australia and New Zealand Clinical Trials Registry (ACTRN12611 
000262909). Registered 10 March 2011. 
Keywords: Cost-effectiveness, Cost-utility, Diabetes, Lifestyle intervention, Prevention 
Background 
Type 2 diabetes is a major cause of death and disability 
worldwide, with its health burden falling increasingly 
upon the low- and middle-income countries (LMICs) 
[1]. India has the second-largest number of people with 
diabetes in the world, with an estimated 77 million 
adults with the disease (21% of diabetes cases in LMICs) 
[1]. More worryingly, the prevalence of diabetes and the 
number of premature deaths due to diabetes are increas-
ing rapidly in India and are likely to continue to impose 
a heavy economic burden on India’s healthcare system 
in the coming decades [2]. Identifying and implementing 
effective, cost-effective, and potentially scalable measures 
to control the diabetes epidemic is, therefore, a health 
policy priority for India. 
Evidence from randomized controlled trials (RCTs) 
shows that lifestyle interventions for individuals at high 
risk of developing type 2 diabetes can reduce progres-
sion to diabetes [3], microvascular complications [4], 
and cardiovascular events [4], and improve cardiovascu-
lar risk factors [5, 6] and health-related quality of life 
(HRQoL) [7, 8]. Currently available evidence shows that 
lifestyle intervention is generally cost-effective in high-
risk individuals for diabetes, but is based overwhelmingly 
on studies conducted in high-income countries [8]. 
Comparable studies from LMICs are scarce but are 
needed because interventions shown to be cost-effective 
in high-income countries are not generalizable to LMICs 
due to the differences in healthcare infrastructure, 
healthcare costs, and cost-effectiveness thresholds be-
tween these settings [9]. Furthermore, resources are 
much more limited in LMICs than in high-income 
countries, so cost-effective interventions in high-income 
countries may not be affordable in LMICs. 
Only one previous study, the Indian Diabetes Preven-
tion Programme (IDPP), has undertaken a cost-
effectiveness analysis of lifestyle intervention among 
high-risk individuals for developing diabetes in India. 
The IDPP estimated a cost of US$1052 to prevent one 
case of diabetes over 3 years [10]. From an economic 
standpoint, the IDPP study had several limitations. First, 
it included only screening and intervention costs when 
assessing direct medical costs. By excluding healthcare 
use outside the immediate IDPP intervention compo-
nents, the resulting cost estimates are likely to be either 
under- or overestimates of the incremental health sys-
tem costs of the program, which are typically of greater 
policy interest. The cost-effectiveness of the IDPP from 
a societal point of view is also not known. Second, IDPP 
included only people with impaired glucose tolerance 
(IGT). While people with IGT are at high risk of devel-
oping diabetes, high-risk groups in the real world en-
compass a much broader subset of the population. 
These high-risk people without IGT but with other car-
diovascular risk factors may outnumber people with IGT 
and require effective measures for diabetes risk reduc-
tion [11]. For example, in India, only about 4% of the 
adult population (20 years and older) have IGT, which is 
only 16% of people with prediabetes in India [12]. Fi-
nally, the IDPP study used a clinical endpoint (i.e., dia-
betes incidence) as an effectiveness measure and did not 
gather the information that could be used to generate 
quality-adjusted life years (QALYs) for cost-utility ana-
lysis. While lifestyle interventions can reduce diabetes 
incidence, they can also have broader health effects be-
yond glucose measures [5–7]. QALY captures the im-
pact of an intervention on both the quantity and quality 
of life [13]. More importantly, the use of QALY enables 
a comparison of healthcare interventions across different 
medical conditions. This is pertinent, given India’s re-
cent heavy investments in health technology assessments 
(HTAs) for promoting evidence-based choices to adopt 
health interventions by the health system [14]. 
We conducted a cluster-RCT of a community-based 
peer-support lifestyle intervention among individuals at 
high risk of developing type 2 diabetes in the Indian 
state of Kerala, the Kerala Diabetes Prevention Program 
(K-DPP) [6, 15]. After a mean follow-up of 2 years, the 
intervention resulted in a non-significant 12% relative 
risk reduction (relative risk 0.88, 95% CI 0.66 to 1.16) in 
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diabetes incidence [6], significant 0.69% (95% CI 0.10– 
1.29%) absolute risk reduction in 10-year cardiovascular 
risk [16], and significant improvements in certain key 
cardiovascular risk factors, including physical activity, 
diet, tobacco use, alcohol use, and lipids, and HRQoL [6, 
16, 17]. Resource constraints imply, however, that in 
addition to clinical effectiveness, any decision to adopt a 
health promotion program by a health system will also 
depend on its cost-effectiveness. We, therefore, report 
here the findings of the trial-based cost-effectiveness 
analysis of the K-DPP intervention from the health sys-
tem and societal perspectives. 
Methods 
Study design, setting and participants 
Details of the K-DPP study design have been previously 
published [15]. Briefly, 60 polling areas (electoral divi-
sions) were randomly selected from the Neyyattinkara 
taluk (subdistrict) in the Trivandrum district of Kerala 
state. These polling areas were randomly assigned (1:1) 
to a control group or a lifestyle intervention group using 
a computer-generated randomization sequence by an in-
dependent person. Individuals (age 30–60 years) identi-
fied from the electoral roll of the selected polling areas 
were approached at their homes by trained field staff. 
Those with a history of diabetes or other major chronic 
conditions (e.g., cardiovascular disease, cancers), taking 
medications affecting glucose tolerance (e.g., steroids), 
illiterate in the local language, and pregnant women 
were excluded. Eligible individuals underwent a two-step 
screening procedure involving a diabetes risk score and 
a 2-h 75-g oral glucose tolerance test (OGTT) [18]. The 
Indian Diabetes Risk Score (IDRS) [19], which comprises 
age, family history of diabetes, physical activity, and 
waist circumference, was administered by trained staff. 
Those with an IDRS score of ≥ 60 were invited to attend 
clinics organized in local neighborhoods to undergo an 
OGTT. Those diagnosed with diabetes based on the 
American Diabetes Association (ADA) criteria (fasting 
plasma glucose [FPG] ≥ 7.0 mmol/l and/or 2-h plasma 
glucose [2-h PG] ≥ 11.1 mmol/l) [20] were excluded and 
referred to healthcare facilities for treatment and care. 
The remaining individuals who had a high diabetes risk 
score (IDRS ≥ 60) and did not have diabetes on the 
OGTT were recruited to the trial. Of these, 69% had 
prediabetes, and 31.0% had normal glucose levels based 
on the ADA criteria [20]. 
Intervention 
The development and cultural adaptation of the inter-
vention program have been explained in detail elsewhere 
[21]. Briefly, the intervention was designed based on a 
needs assessment study [22] along with cultural adapta-
tion from the components of evidence-based peer-
support interventions tested in high-income countries, 
including Finland, Australia, and the USA [21]. The 
intervention consisted of 15 group sessions delivered 
over 12 months. All sessions were conducted in local 
neighborhoods in community buildings (e.g., schools, 
community halls) during Saturdays or Sundays at times 
that were convenient for participants. The K-DPP staff 
delivered introductory sessions (60–90 min/session) to 
introduce the group participants to the program and its 
mentoring style. Experts in the field of diabetes, nutri-
tion, and physical activity delivered two half-day sessions 
focusing on prevention and management strategies for 
diabetes. Trained peer leaders (one male and one female 
per group), who were identified from within the group, 
delivered 12 sessions (60–90 min/session) at 1-month in-
tervals on average. The peer group size varied from 10 
to 23 participants. Content of the peer group sessions, 
and the selection and training of peer leaders have been 
reported elsewhere [6, 17]. The objectives of the lifestyle 
intervention were to increase physical activity, promote 
healthy eating habits and tobacco cessation, reduce alco-
hol consumption, maintain ideal bodyweight, and ensure 
adequate sleep. Peer leaders were given a handbook to 
assist them in running group sessions. Participants re-
ceived resource materials including a handbook, a work-
book, and a health education booklet to improve their 
knowledge on diabetes, risk factors, and prevention 
strategies and to monitor their progress towards lifestyle 
change. Bodyweight was measured during the peer 
group sessions. Additionally, participants were encour-
aged to have regular contact with their peer leaders out-
side the group sessions, and engage in community 
activities such as kitchen gardening, yoga training, and 
walking groups. Local resource persons (LRPs) identified 
for each group assisted the peer leaders in organizing 
the peer group sessions. Control group participants re-
ceived a health education booklet on standard advice 
about lifestyle change. 
Costs 
We estimated costs from the health system and societal 
perspectives, in accordance with the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) 
statement [23] and cost-effectiveness analysis guidelines 
[24, 25]. Research costs were excluded from the analyses. 
Health system costs 
To estimate health system costs, we considered only dir-
ect medical costs, which included screening costs, inter-
vention costs, and healthcare utilization costs. 
Screening and intervention costs Most of our screen-
ing costs were driven by the need to identify high-risk 
individuals for the trial in a short period of time through 
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home visits and community-based clinics [18, 26]. From 
this perspective, many of the screening costs were con-
sidered to be research costs. In a non-research setting in 
India, health workers screen and identify high-risk indi-
viduals for diabetes as part of their ongoing clinical care 
[27]. In line with this, as well as based on previous dia-
betes prevention studies [10, 28], we considered only 
IDRS and OGTT costs for this cost-effectiveness ana-
lysis. The unit cost of these tests was obtained from the 
study accounts register (see Additional file 1: Table S1). 
A detailed description of the methods for estimating the 
intervention costs has been published previously [6]. 
Apart from peer leaders (60), the staff involved in deliv-
ering the group sessions were intervention manager (1), 
intervention assistant (1), LRPs (30), and experts (4). Al-
though a time-use survey was not undertaken, a detailed 
log was maintained for the staff time spent on various 
intervention activities, and this time was valued based 
on staff remuneration rates. Cost of printing resource 
materials and operations (training, phone calls, travel, 
rent for intervention venues, and overheads) was based 
on the expenditure on these items. The unit cost of 
intervention components was obtained from the study 
accounts register (see Additional file 1: Table S1). 
Healthcare utilization costs Information on healthcare 
use (i.e., outpatient visits, inpatient days, and medication 
use) from public and private facilities was collected an-
nually based on self-reports or from participants’ pre-
scriptions, medical records, and bills, if available. In 
Kerala, the majority of outpatient (63.5%) and inpatient 
care (66%) are sought from private facilities [29]. Private 
health expenditure in Kerala, primarily household out-
of-pocket payments, accounts for 73.4% of total health 
expenditure [30]. Thus, ignoring the utilization of ser-
vices from private health facilities (and associated ex-
penses) will significantly underestimate the true health 
system costs. The unit cost of outpatient visits and in-
patient days at public and private health facilities was 
based on the World Health Organization (WHO) 
CHOICE (CHOosing Interventions that are Cost-
Effective) estimates for India (see Additional file 1: Table 
S1) [31]. The cost of medications was obtained through 
participants’ self-reports or from prescriptions, medical 
records, and bills, if available. 
Societal costs 
To estimate societal costs, we considered direct medical 
costs, direct non-medical costs, and indirect costs. Direct 
non-medical costs included expenses incurred by partici-
pants for transport, food, and accommodation while seek-
ing healthcare (self-reported), and for the time spent 
traveling to and attending group sessions. The interven-
tion participants (including peer leaders) spent, on 
average, 30min of travel time and 60min in attending one 
group session. These times were valued at the minimum 
hourly wage of an unskilled worker employed in the agri-
cultural sector in India [32]. Indirect costs were calculated 
by assuming that each inpatient stay resulted in a loss of 
9 h of paid work, and each outpatient visit resulted in a 
loss of half a day (4.5 h) of paid work [32]. These lost days 
of productivity were valued at the minimum hourly wage 
of an unskilled worker employed in the agricultural sector 
in India for all participants [32]. This wage rate was used 
primarily for two key reasons: (1) the study population is 
predominantly rural, and the main source of employment 
for most people is the agricultural sector, which is primar-
ily unskilled work; (2) if homemakers, retired, and un-
employed wish to work at all, then they have to balance 
work with their home responsibilities, and unskilled work 
is probably what is most readily available to them. All 
costs in Indian Rupees (INR) were inflated for the year 
2018 using the Consumer Price Index for India [33] and  
were converted to US dollars using an exchange rate of 
US$1 = INR68.4 [33]. 
Effects 
We assessed effectiveness in terms of the number of dia-
betes cases prevented and of QALYs, as recommended 
by the CHEERS statement [23] and cost-effectiveness 
analysis guidelines [24, 25]. The number needed to treat 
(NNT) to prevent one case of diabetes was estimated as 
the inverse of absolute risk reduction, i.e., the difference 
in diabetes incidence between the study groups [34]. 
There was no statistically significant difference in the ab-
solute risk reduction in diabetes incidence (2.1% (95% CI 
− 2.9 to 7.1%, p = 0.405)) at 2 years. Our trial was likely 
underpowered to detect a significant difference, given 
the inclusion of participants with normal plasma glucose 
(31% by the ADA criteria; 65.9% by the WHO criteria) 
[35], and the short follow-up. Based on the memorable 
adage “absence of evidence is not evidence of absence” 
[36], Briggs and O’Brien argue that analysts should focus 
on estimating cost-effectiveness based on the joint ana-
lysis of costs and effects rather than relying on a step-
wise approach that conditions the analysis on the 
statistical significance of cost or effect differences be-
tween treatment groups in the first step [37]. This is 
now recommended in many cost-effectiveness guidelines 
[24, 25] and is increasingly seen in the health economics 
literature [38–40]. 
QALYs were estimated based on the utility values de-
rived from the 36-item Short Form (SF-36) health survey 
[41]. SF-36 was administered at baseline, 1 year, and 
2 years. The SF-36 is divided into eight scales (physical 
functioning, role limitation—physical, role limitation— 
emotional, bodily pain, general health, mental health, so-
cial functioning, and vitality) and two domains (physical 
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component summary and mental component summary). 
Scores for each of the scales and domains range from 0 
to 100, with higher scores indicating a better quality of 
life. The SF-36 data were converted into a six-
dimensional health state called the Short Form 6 Dimen-
sion (SF-6D), whose score ranges between 0.29 (worse 
health) and 1.00 (full health) [42]. The SF-6D data were 
converted to QALYs using the area under the curve 
method [43]. 
Statistical analysis 
This cost-effectiveness analysis was conducted using 
standard methods of trial-based economic evaluation 
[25]. The analyses were performed using the intention-
to-treat approach. Missing values for healthcare use, dia-
betes incidence, and QALYs were imputed using the last 
observation carried forward method based on the miss-
ing completely at random assumption [44]. Generalized 
estimating equations (GEE) using log-binomial models 
with an exchangeable working correlation structure and 
robust standard errors to account for clustering by poll-
ing areas were used to estimate the absolute risk reduc-
tion in diabetes incidence between study groups. 
Generalized linear models (GLM) with gamma family 
and log link components were used to estimate the in-
cremental costs and QALYs [45]. Standard errors for in-
cremental QALYs were estimated by accounting for 
clustering by polling areas [46]. QALY models were ad-
justed for the baseline utility values (SF-6D). The incre-
mental cost-effectiveness ratio (ICER) was estimated by 
multiplying the incremental costs with the NNT for dia-
betes incidence or by dividing the incremental costs with 
the incremental QALYs. 
We estimated uncertainty in the estimates of costs and 
effects by non-parametric bootstrapping method, which 
was conducted by resampling without replenishment 
from the original dataset [47]. In each of the 1000 itera-
tions, GEE (for diabetes incidence) or GLM (for costs 
and QALYs) were run, and the incremental costs, abso-
lute risk reduction in diabetes incidence, and incremen-
tal QALYs were estimated. These estimates are 
presented visually using a cost-effectiveness plane and a 
cost-effectiveness acceptability curve. The cost-
effectiveness plane shows uncertainty in the costs and ef-
fects in four quadrants, namely southeast (intervention 
is less costly and more effective than the control group), 
northeast (intervention is more costly and more effective 
than the control group), southwest (intervention is less 
costly and less effective than the control group), and 
northwest (intervention is more costly and less effective 
than the control group). The cost-effectiveness accept-
ability curve shows the probability for the intervention 
to be cost-effective, compared to the control group, at 
various willingness to pay (WTP) thresholds. WTP was 
based on the gross domestic product (GDP) per capita, 
with an intervention deemed to be cost-effective if the 
ICER is less than three times GDP per capita, as recom-
mended by the WHO-CHOICE [31]. According to the 
International Monetary Fund, the GDP per capita for 
India in 2018 was US$2036 [33]. Analyses were per-
formed with a 2-year time horizon (average length of K-
DPP follow-up). The discount rate for costs and effects 
for the base-case scenario was 3% per annum, as recom-
mended by the Panel on Cost-Effectiveness in Health 
and Medicine [24]. 
Additionally, we conducted the following one-way and 
multi-way sensitivity analyses. We allowed the cost of group 
sessions (the key driver of intervention costs) and effects to 
vary by a range of plausible values (i.e., ± 10, ± 20, 
and ± 30%) in a non-research setting, based on as-
sumptions made in previous lifestyle-based diabetes 
prevention programs [28, 48]. This was done in three 
ways: the cost was allowed to vary, but the effects 
were kept fixed; the effects were allowed to vary, but 
the cost was kept fixed; and both costs and effects were 
allowed to vary. Since a 3% discount rate is based on 
guidelines developed for high-income countries, we dis-
counted costs and effects using different rates (5% and 
10% per annum) that are recommended for LMICs, in-
cluding India [49]. Finally, we conducted multiple imput-
ation (MI) analysis, accounting for clustering by polling 
areas [50, 51] to assess the impact of missing data on 
costs, diabetes incidence, and QALYs on the main results. 
MI was performed using chained equations with 10 impu-
tations, and GEE and GLM models were run on each of 
the 10 imputed datasets, and the results were combined 
using Rubin’s rule  [52]. Analyses were performed using 
Stata software (version 15.0; StataCorp, TX, USA) and 
Microsoft Office Excel 2018 (Microsoft Corporation, 
Redmond, WA, USA). 
Results 
A total of 1007 participants (500 in the intervention 
group and 507 in the control group) were recruited 
into the trial. All 60 clusters and 964 (95.7%) partici-
pants (96.4% in the intervention group and 95.1% in 
the control group) were followed up at 2 years. The 
baseline characteristics of clusters and participants 
were similar in the two study groups (see Add-
itional file 1: Table S2) [35]. 
Costs 
Table 1 summarizes the per capita cost over the 2-year 
trial period by the study group. Total intervention costs 
amounted to US$12,096 in the intervention group 
(US$24.2 per participant) and US$389 in the control 
group (US$0.8 per participant). Over 2 years, the out-
patient and medication costs were lower in the 
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Table 1 Average per capita cost by study group over 2 years 
Control group (N = 507) Intervention group (N = 500) 
Direct medical costs 
Screening 
IDRS 0.1 0.1 
OGTT 4.1 4.1 
Intervention 
Group sessions 
Introductory sessions 0 3.5 
DPES 0 2.1 
Peer group sessions 0 7.1 
Training of peer leaders and LRPs 0 2.8 
Resource materials 0.8 5.3 
Community activities 0 0 
Overheads 0 3.3 
Subtotal 0.8 24.2 
Healthcare use 
Outpatient visits 62.3 50.0 
Inpatient days 47.5 50.5 
Medications 186.8 174.8 
Subtotal 296.6 275.2 
Total cost from a health system perspective 301.6 303.6 
Direct non-medical costs 
Transport, food, and accommodation costs while seeking healthcare 12.7 12.2 
Travel time to attend group sessions 0 2.1 
Time spent attending group sessions 0 4.1 
Subtotal 12.7 18.4 
Indirect costs (productivity loss due to illness) 47.2 45.8 
Total cost from a societal perspective 361.5 367.8 
IDRS Indian Diabetes Risk Score, OGTT oral glucose tolerance test, DPES diabetes prevention education sessions, LRP local resource person. Costs are expressed in 
2018 US$ 
intervention group by ~ US$12, compared to the control 
group. From a health system perspective, the mean cost 
per participant was US$303.6 in the intervention group 
and US$301.6 in the control group, resulting in an incre-
mental cost of US$2.0. The total non-medical costs were 
higher in the intervention group compared to the con-
trol group by US$5.7. From a societal perspective, the 
mean cost per participant was US$367.8 in the interven-
tion group and US$361.5 in the control group, resulting 
in an incremental cost of US$6.2. 
Effectiveness 
At 2 years, the absolute risk reduction in diabetes inci-
dence was 2.1% (95% CI − 2.9 to 7.1%, p = 0.405), result-
ing in an NNT of 47.6. The average QALYs gained were 
consistently higher in the intervention group compared 
to the control group in both the first (0.81 vs. 0.79) and 
second years (0.84 vs. 0.81). Overall, during the 2-year 
trial period, participants in the intervention group ac-
crued more QALYs than the control participants (1.65 
vs. 1.61) with a mean difference of 0.04 (95% CI 0.02 to 
0.07, p = 0.002). 
Cost-effectiveness 
Table 2 shows the incremental cost-effectiveness of life-
style intervention over 2 years. From a health system 
perspective and compared with the control group, the 
lifestyle intervention costs US$95.2 per diabetes case 
prevented and US$50.0 per QALY gained. From a soci-
etal perspective and compared with the control group, 
the lifestyle intervention costs US$295.1 per diabetes 
case prevented and US$155.0 per QALY gained. A 3% 
discount rate per annum did not alter the ICERs appre-
ciably. Figure 1 shows the cost-effectiveness plane. For 
diabetes cases prevented, from a health system 
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Table 2 Incremental cost-effectiveness of the lifestyle intervention versus control group over 2 years 
Cost per diabetes case prevented Cost per QALY gained 
Health system perspective Societal perspective Health system perspective Societal perspective 
Base-case analysis 
Without discounting 95.2 295.1 50.0 155.0 
With discounting (3% per annum) 95.1 292.5 49.0 150.8 
Sensitivity analyses 
Cost of group sessions only 
10% increase 157.1 357.0 82.5 187.5 
20% increase 219.0 414.1 115.0 217.5 
30% increase 276.1 476.0 145.0 250.0 
10% decrease 38.1 238.0 20.0 125.0 
20% decrease Dominated* 176.1 Dominated* 92.5 
30% decrease Dominated* 114.2 Dominated* 60.0 
Intervention effectiveness only 
10% increase 87.0 269.7 45.5 140.9 
20% increase 80.0 248.0 41.7 129.2 
30% increase 74.0 229.4 38.5 119.2 
10% decrease 105.2 326.1 55.6 172.2 
20% decrease 117.6 364.6 62.5 193.8 
30% decrease 133.4 413.5 71.4 221.4 
Both cost of group sessions and intervention effectiveness 
10% increase 143.6 326.3 75.0 170.5 
20% increase 184.0 348.0 95.8 181.3 
30% increase 214.6 370.0 111.5 192.3 
10% decrease 42.1 263.0 22.2 138.9 
20% decrease Dominated* 217.6 Dominated* 115.6 
30% decrease Dominated* 160.1 Dominated* 85.7 
Discounting 
5% per annum 116.8 292.5 60.5 151.5 
10% per annum 169.4 292.7 88.4 152.7 
MI analysis 
Lifestyle intervention vs. control group 99.2 302.1 56.0 157.5 
QALY quality-adjusted life year, MI multiple imputation 
*Lifestyle intervention was less costly and more effective than the control group 
perspective, the lifestyle intervention was associated with 
higher effects and lower costs in 41.6% of bootstrap esti-
mates (southeast quadrant), and with higher effects and 
higher costs in 42.2% of bootstrap estimates (northeast 
quadrant). From a societal perspective, the correspond-
ing figures were 39.8% and 43.3%. For QALYs gained, 
from a health system perspective, the lifestyle interven-
tion resulted in higher effects and lower costs in 49.9% 
of bootstrap estimates (southeast quadrant), and in 
higher effects and higher costs in the remaining 50.1% of 
bootstrap estimates (northeast quadrant). From a soci-
etal perspective, the corresponding figures were 47.9% 
and 52.1%. Figure 2 shows the cost-effectiveness 
acceptability curve. For diabetes cases prevented, the 
probability for the intervention to be cost-effective was 
84.0% and 83.1% at a WTP of < US$6108 (three times 
India’s GDP per capita) from the health system and soci-
etal perspectives, respectively. For QALYs gained, the 
corresponding figures were 99.1% and 97.8%. 
Sensitivity analyses 
Table 2 shows the results of sensitivity analyses. ICERs 
were more sensitive to changes in the cost of group ses-
sions than to the changes in effects. For example, from a 
health system perspective, a 10% increase in the cost of 
group sessions increased the ICER from US$95.2 to 
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Fig. 1 Cost-effectiveness plane. Absolute risk reduction in diabetes incidence: health system perspective (a) and societal perspective (b). QALY 
gained: health system perspective (c) and societal perspective (d). QALY, quality-adjusted life year 
US$157.1, whereas the same increase in absolute risk re-
duction in diabetes incidence resulted in an ICER of 
US$87.0. For diabetes cases prevented, from a health 
system perspective, changes in the costs and effects re-
sulted in ICERs ranging between dominance (lifestyle 
intervention was less costly and more effective than the 
control group) and US$276.1. From a societal perspec-
tive, the corresponding figures were US$114.2 and 
US$476.0. For QALYs gained, from a health system per-
spective, changes in the costs and effects resulted in 
ICERs ranging between dominance and US$145.0. From 
a societal perspective, the corresponding figures were 
US$60.0 and US$250.0. Discounting of costs and effects 
at 5% or 10% per annum and MI analysis did not alter 
the main results appreciably. 
Discussion 
This trial-based cost-effectiveness analysis showed that 
the incremental cost of the lifestyle intervention was 
US$95.2 and US$295.1 per diabetes case prevented, and 
US$50.0 and US$155.0 per QALY gained, from the 
health system and societal perspectives, respectively, 
over 2 years. The uncertainty analysis indicates that 
more than 83% (for diabetes cases prevented) and 100% 
(for QALYs gained) of bootstrap estimates were cost-
effective (<US$6108) from both the perspectives. In 
addition, the probability for the intervention to be cost-
effective was more than 83% for diabetes cases prevented 
and 97% for QALYs gained from both the perspectives. 
Discounting costs and effects at a rate of 3% per annum 
did not alter the results appreciably. In all case scenarios 
in the sensitivity analyses for both the effects, the ICERs 
remained below the cost-effectiveness threshold (i.e., 
US$6108). 
In our study, the difference in intervention costs be-
tween study groups (US$23.4) was accompanied by 
lower (roughly equal) outpatient, medication, and indir-
ect costs in the intervention group, resulting in a negli-
gible cost difference between study groups from the 
health system and societal perspectives. This could be 
due to the positive intervention effects on healthy life-
style behaviors including physical activity, diet, tobacco 
use, and alcohol use [6, 17]. In LMICs, so far, two trial-
based analyses [10, 53] and a modeling study [54] have 
evaluated the cost-effectiveness of lifestyle-related dia-
betes prevention programs. In the IDPP study, the ICER 
was US$1052 per case of diabetes prevented in those 
with IGT over 3 years from a health system perspective 
[10]. In the DMagic trial from Bangladesh, the ICER for 
a community mobilization intervention in people with 
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Fig. 2 Cost-effectiveness acceptability curve. Diabetes cases prevented: health system perspective (a) and societal perspective (b). QALY gained: 
health system perspective (c) and societal perspective (d). QALY, quality-adjusted life year 
intermediate hyperglycemia was INT$6518 per case of 
diabetes prevented (or INT$2551 per disability-adjusted 
life years averted) over 2 years from a health system per-
spective [53]. Additionally, a modeling study from China 
estimated that among those with IGT, diet, and physical 
activity interventions were cost-saving over 40 years 
from a societal perspective [54]. ICERs in our study can-
not be directly compared with ICERs from these other 
LMIC studies, given the differences in cost perspectives, 
population groups, and effectiveness measures used. 
However, our study ICERs suggest higher levels of cost-
effectiveness than those reported in high-income coun-
tries even after adjusting for differences in income per 
capita [8]. For example, in the US Diabetes Prevention 
Program (DPP), the cost per QALY gained was US$31, 
512 over 3 years from a health system perspective [28], 
indicating an ICER that is 630 times as high as our esti-
mate (US$50 per QALY), whereas the US GDP per 
capita is 31 times as high as India’s GDP per capita [33]. 
While the NNT to prevent one case of diabetes in 
our study (47.6) was larger than that reported in the 
IDPP (6.4) [10] and US DPP (6.9) [28], the cost per 
case of diabetes prevented was much lower in our 
study. The IDPP and US DPP recruited people with 
IGT, whereas our study included participants based 
on a high diabetes risk score, with the majority hav-
ing isolated impaired fasting glucose (i-IFG) (57.5%) 
[35]. Currently available evidence suggests that life-
style interventions that are effective in reducing dia-
betes risk in people with IGT are not effective in 
those with i-IFG [11]. We estimated QALYs based 
on the preference-based health utility values derived 
from the SF-36 [41]. A review of 23 studies found 
that SF-36 provided the smallest change in health 
utility values, which generally translate to less favor-
able ICERs, compared to EuroQol 5D and other 
HRQoL scales [55]. Therefore, the QALY gain seen 
in our trial is likely to be a conservative estimate. 
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Nevertheless, the magnitude of QALY gain (0.04) ob-
served  in  our study  is  similar to or higher than that  
seen with many other lifestyle-related diabetes pre-
vention interventions that are more intense or ex-
pensive [8]. For example, in the US DPP, the 
difference in QALYs between the lifestyle interven-
tion and placebo groups was 0.02 at 2 years [28]. In 
the Let's Prevent Diabetes cluster-RCT from the UK, 
the QALY gain with the lifestyle intervention was 
0.04 over 2 years [38]. 
Our study has several strengths. To our knowledge, 
this is the first study from an LMIC setting to pro-
vide comprehensive evidence on the cost-
effectiveness of lifestyle intervention in high-risk in-
dividuals for type 2 diabetes from both the health 
system and societal perspectives. The K-DPP trial 
was conducted in the Indian state of Kerala, which 
has the highest prevalence of diabetes in India with 
a high burden of several cardiovascular risk factors 
[12, 56–58]. The epidemiological transition that is 
currently occurring in Kerala is indicative of what 
will happen in other states in India in the coming 
years, as well as in many other LMICs [59]. There-
fore, evaluating the cost-effectiveness of appropriate 
lifestyle intervention strategies in this setting will en-
able proactive policymaking in other states of India 
as well as other LMICs. More importantly, in our 
study, we included high-risk individuals across all 
categories of glucose tolerance [35]. This, along with 
the pragmatic nature of intervention delivery, ad-
vances the generalizability of our study results to a 
broader high-risk population of India. While Kerala’s 
literacy rate, health indicators, and health system are 
comparatively better than most Indian states, we be-
lieve that our intervention model can be adapted to 
other Indian states and possibly to other South 
Asian countries. Factors likely to facilitate its appli-
cation in other Indian settings include the relatively 
low cost of the intervention, the large presence of 
civil society organizations and self-help groups in 
rural Indian settings [60], and the recent government 
efforts to revitalize primary care and prevention 
strategies for non-communicable diseases [27]. Cost 
and QALY data were available for the vast majority 
of study participants (95.1%). We estimated uncer-
tainty in the costs and effects, unlike many other 
trial-based cost-effectiveness analyses of diabetes pre-
vention programs [8]. Finally, the main results were 
robust to several types of sensitivity analyses. 
Our study has some limitations. These include, the 
relatively short follow-up of 2 years, which did not 
permit an assessment of the long-term cost-
effectiveness of the intervention. However, by adopt-
ing a 2-year time horizon, we likely underestimated 
the effects, with the health benefits of a lifestyle inter-
vention generally occurring over the longer term 
[61]. Another key limitation is that information on 
healthcare use was mainly self-reported and, there-
fore, susceptible to recall bias. However, this bias 
was reduced to some extent, as approximately 40% 
of healthcare use data was obtained from partici-
pants’ medical records, prescriptions, and bills. 
Moreover, in the Indian context, people tend to have 
good recall as a large proportion of total health ex-
penditure (India’s average, 58.7% vs. 67% in Kerala) 
is paid out-of-pocket at the point of service delivery 
[30]. It is likely that homemakers, retired, and un-
employed people have a lower opportunity cost of 
time than working individuals and have a greater 
likelihood of attending the peer group sessions and 
implementing steps to lower the risk of diabetes. On 
the other hand, time costs saved in the future from 
delayed or prevented diabetes would be much higher 
for the working age population. Exploring such het-
erogeneity in the costs and benefits of the interven-
tion can yield important policy insights for scaling 
up the intervention. However, it was not feasible to 
undertake such analyses due to concerns about lim-
ited statistical power, particularly when there was no 
statistically significant difference in the primary out-
come (i.e., diabetes incidence). The minimum hourly 
wage of an unskilled worker employed in the agri-
cultural sector would be an underestimate of oppor-
tunity costs for a few participants who were working 
in higher-level jobs. We used the GDP per capita 
based WHO-CHOICE threshold to determine the 
cost-effectiveness of our intervention. Although this 
threshold is widely used in LMICs [62], it has been 
criticized for ignoring opportunity costs imposed on 
health systems [62, 63]. However, our intervention 
remains cost-effective even with the (much lower) 
India-specific opportunity-based cost-effectiveness 
thresholds (US$136.7 to US$915.6 per QALY 
gained for the year 2018), estimated by Woods et al. 
[63]. Finally, SF-36 is a generic instrument to meas-
ure overall HRQoL, and it could be insensitive to 
particular aspects of certain health conditions [13], 
which could be better captured by diabetes-specific 
HRQoL scales [64]. 
Conclusion 
In this trial-based economic analysis, we have demon-
strated that implementing a low-cost peer-support lifestyle 
intervention in community settings for individuals at high 
risk of developing diabetes was cost-effective in a low- and 
middle-income setting. Future work is needed to deter-
mine whether this persists over a longer period of time 
and when the intervention model is taken to scale. A 
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recent scale-up of K-DPP to more than 15,000 trained 
peer leaders who delivered the program to more than 370, 
000 people in Kerala has demonstrated very promising re-
sults [65]. The findings of this economic evaluation can 
help underpin the more effective allocation of scarce 
healthcare resources for community-based lifestyle inter-
ventions for preventing diabetes in India, given the coun-
try’s ongoing efforts to establish evidence-based HTA to 
ensure value for money in the health budget [14]. 
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